The 'Transformative' Eli Lilly Drug That Could Top $25 Billion In Annual SalesInvestors Business Daily • 09/22/22
UBS: LIlly's Type 2 diabetes and obesity treatment could be 'one of the best-selling drugs in history'Market Watch • 09/22/22
FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of TypePRNewsWire • 09/21/22
AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts sayMarket Watch • 09/14/22
Eli Lilly and Company (LLY) Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/13/22
Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis TrialsPRNewsWire • 09/08/22
Eli Lilly and Company (LLY) Citigroup 17th Annual BioPharma Conference (Transcript)Seeking Alpha • 09/08/22
This outperforming fund manager looks for four traits in stocks — and has found them in these nine companiesMarket Watch • 08/30/22
8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends24/7 Wall Street • 08/30/22